Prognostic Significance of the Ratio of Surgically Resected to Radiologically Detected Lung Nodules in Patients with Metastatic Osteosarcoma
Overview
Authors
Affiliations
Patients And Methods: Data from patients with metastatic osteosarcoma who underwent metastasectomy between January 2009 and December 2020, in a single center, were reviewed. The relationships between survival and the SR/RD ratio, timing of lung metastases, number of nodules, laterality, and presence of tumor necrosis at first metastasectomy were investigated.
Results: Among the 125 metastatic osteosarcoma patients, 80 patients had an SR/RD ratio ≤1. The median duration of follow-up was 72 months, ranging from 6 to 118 months. The five-year overall survival (OS) and postmetastasectomy event-free survival (EFS) for all patients were 36.5% and 18.1%, respectively. The five-year OS of patients with a low SR/RD ratio was 49.6% and that of patients with a high SR/RD ratio was 11.8 (P = 0.001). The two-year postmetastasectomy EFS rates of the high and low ratio groups were 24.1% and 9.4%, respectively (P = 0.001). The SR/RD ratio, number of nodules, and tumor necrosis had significant effects on OS and postmetastasectomy EFS in univariate analysis. A Cox proportional hazard model demonstrated that tumor necrosis and an SR/RD ratio >1 were associated with OS (HR = 1.8 and 2.01) and postmetastasectomy EFS (HR = 1,69 and 1.97).
Conclusions: A high SR/RD ratio of greater than 1 and poor tumor necrosis were significantly associated with poor survival among patients with metastatic osteosarcoma who had lung metastasectomy. The high SR/RD ratio may be a surrogate outcome for incomplete metastatic tumor resection.
Noleto da Nobrega Oliveira R, Peres C, Oliveira A, Onyeji P, Kemczenski F Pediatr Surg Int. 2024; 41(1):34.
PMID: 39699640 DOI: 10.1007/s00383-024-05934-3.
Longhi A, Marrari A, Tetta C, Parmeggiani A, Parise O, Ferrari C Cancers (Basel). 2024; 16(21).
PMID: 39518034 PMC: 11544818. DOI: 10.3390/cancers16213593.
Kuo C, Malvar J, Chi Y, Kim E, Shah R, Navid F Cancer Med. 2023; 12(20):20231-20241.
PMID: 37800658 PMC: 10652329. DOI: 10.1002/cam4.6491.
Improving survival after pulmonary metastasectomy for sarcoma: analysis of prognostic factors.
Shell D Gen Thorac Cardiovasc Surg. 2023; 71(5):263-271.
PMID: 36631707 DOI: 10.1007/s11748-023-01905-y.